Cirtuvivint - Biosplice Therapeutics
Alternative Names: NSC-835563; SM-08502Latest Information Update: 07 Mar 2025
At a glance
- Originator Samumed
- Developer Biosplice Therapeutics
- Class Amides; Antineoplastics; Isoquinolines; Piperazines; Pyrazoles; Pyridines; Small molecules
- Mechanism of Action DYRK kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Acute myeloid leukaemia; Colorectal cancer; Myelodysplastic syndromes; Non-small cell lung cancer; Prostate cancer; Solid tumours
- Preclinical Haematological malignancies
Most Recent Events
- 20 Feb 2025 Biosplice Therapeutics suspends phase I trial as per CTEP PIO in Myelodysplastic syndromes (Second-line therapy or greater, Combination therapy, Monotherapy) in USA (PO) (NCT06484062)
- 17 Sep 2024 Biosplice Therapeutics establishes CRADA with National Cancer Institute (NCI) for the development of Cirtuvivint in Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)
- 12 Sep 2024 Phase-I clinical trials in Acute myeloid leukaemia (Monotherapy, Second-line therapy or greater) in USA (PO) (NCT06484062)